☆ 4.2 Meeting Abstract

Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL)

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Journal

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Volume 23, Issue -, Pages S451-S451

Publisher

CIG MEDIA GROUP, LP

Keywords

EBV associated lymphoproliferative disorder; non-Hodgkin lymphoma; nivolumab; Phase 2 trial; immunotherapy

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.